Shares of Insulet Corp. (PODD) took a hit in Friday's premarket trading. The reason? The company put out a notice about a voluntary medical device correction for certain lots of its Omnipod 5 Pods. It's the kind of news that tends to make investors a bit queasy, especially when it involves a product that delivers a life-sustaining medication like insulin.
A Small Tear With Big Consequences
Here's the issue: Insulet found a manufacturing defect in specific production lots. The problem is a potential small tear in the internal tubing that delivers the insulin. If that happens, the pod might not deliver the full, prescribed dose.
That's not just an inconvenience. Under-delivery of insulin can lead to high blood glucose levels and, in serious cases, a dangerous condition called diabetic ketoacidosis (DKA). For those who don't live with diabetes, DKA is a critical, life-threatening emergency where the body, starved of insulin, starts burning fat for fuel and produces high levels of blood acids. The company has received 18 reports of serious adverse events linked to this specific tubing issue.
The good news, relatively speaking, is the scale. The affected pods make up only about 1.5% of Insulet's annual global production. The company has also been clear that all other Omnipod products are safe to use, and the problem doesn't affect continuous glucose monitoring (CGM) systems or the readings from those devices.
What the Charts Are Saying
When news like this breaks, the technical picture often gets messy. For Insulet, the stock is currently trading well below its key moving averages—8.63% under its 20-day and 14.45% under its 100-day simple moving average. That paints a bearish picture for the short to medium term. Over the past year, shares are down about 3.5%, and they're hanging out much closer to their 52-week lows than their highs.
The momentum indicators are telling a slightly more conflicted story. The Relative Strength Index (RSI) is sitting at 37.55, which is considered neutral territory—the stock isn't oversold or overbought. Meanwhile, the MACD indicator is showing a bullish crossover, which can sometimes hint at potential upward momentum trying to build.
Put it together, and you get mixed signals. There might be some buyers seeing a dip, but the overall pressure has been to the downside. Traders are watching key resistance at $244.00 and support at $220.00.
Despite the stock's slump, Wall Street analysts haven't thrown in the towel. The consensus rating remains a Buy, with an average price target of $356.64—a figure that looks awfully optimistic from today's levels. Recent moves have included Citigroup lowering its target to $338.00 on March 11 and Truist Securities lowering its target to $360.00 back in February, both while maintaining Buy ratings.
